全細胞醫護科技 OMCL 深 滬
已收盤 02-06 16:00:00 美东时间
37.07
-2.010
-5.14%
華盛通- 最 高39.47
- 今 開38.51
- 成交量 159.72万股
- 最 低 36.69
- 昨 收 39.08
- 總市值 16.64亿
- 52周最高 55.00
- 市盈率 靜 836.79
- 換手率 3.56%
- 52周最低 22.66
- 委 比 -60.05%
- 總股本 4487.65万
- 歷史最高 187.285
- 量 比 1.20
- 振 幅 7.11%
- 歷史最低 12.33
- 每 手 1
- 風險率 6.55%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Omnicell shares are trading lower after the company reported mixed Q4 financial results and issued FY26 adjusted EPS guidance below estimates.
Omnicell shares are trading lower after the company reported mixed Q4 financial...
02-05 22:19
Omnicell veröffentlicht Präsentation zur Strategie für automatisiertes Medikamentenmanagement und Wachstum
Omnicell veröffentlicht Präsentation zur Strategie für automatisiertes Medikamentenmanagement und Wachstum Omnicell Inc. hat eine neue Präsentation veröffentlicht, in der das Unternehmen seine aktuellen Strategien und Innovationen im Bereich der Automatisierung und Digitalisierung der Medikamentenve
02-05 19:55
Omnicell Unveils Strategy to Drive Autonomous Pharmacy Transformation and Recurring Revenue Growth
Omnicell Unveils Strategy to Drive Autonomous Pharmacy Transformation and Recurring Revenue Growth Omnicell Inc. has released an investor presentation outlining its strategy to drive growth in the healthcare technology sector. The company highlighted its position as a leader in medication management
02-05 19:55
Omnicell Q4 EPS misses estimates
Omnicell Q4 EPS misses estimates Overview Healthcare technology provider's fiscal Q4 revenue grew 2% yr/yr Adjusted EPS for fiscal Q4 missed analyst expectations Company launched Titan XT dispensing system to enhance medication management Outlook Omnicell projects 2026 total revenues between $1.215
02-05 19:39
Omnicell Sees Q1 2026 Adj EPS $0.26-$0.36 vs $0.29 Est; Sees Sales $300.000M-$310.000M vs $281.484M Est
2026 GuidanceThe table below summarizes Omnicell's first quarter and full year 2026 guidance: Q1 2026 2026Product BookingsNot provided $510 million - $560 millionAnnual Recurring RevenueNot
02-05 19:33
Omnicell Inc. Q4 2025 GAAP net income drops to USD -2 million, reversing from previous profit
Omnicell Inc. Q4 2025 GAAP net income drops to USD -2 million, reversing from previous profit Omnicell Inc. reported total revenues of USD 314 million for the fourth quarter (Q4) of 2025, reflecting a 2 percent increase compared to the same period in the previous year. For the full year (FY) ended D
02-05 19:33
Omnicell Inc. steigert Gesamtjahresumsatz 2025 auf 1,19 Mrd. USD, plus 7 Prozent
Omnicell Inc. steigert Gesamtjahresumsatz 2025 auf 1,19 Mrd. USD, plus 7 Prozent Omnicell Inc. hat die Finanzergebnisse für das vierte Quartal (Q4) und das Gesamtjahr (FY) 2025 veröffentlicht. Im Q4 2025 erzielte Omnicell Inc. einen Umsatz von 314,00 Mio. USD, was einem Anstieg von 2 Prozent gegenüb
02-05 19:33
Omnicell Earnings Report: Q4 Overview
Omnicell (NASDAQ:OMCL) reported its Q4 earnings results on Thursday, February 5...
02-05 19:32
U.S. RESEARCH ROUNDUP- Ametek, Coca-Cola, Pepsico
U.S. RESEARCH ROUNDUP- Ametek, Coca-Cola, Pepsico Feb 4 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Ametek, Coca-Cola and Pepsico, on Wednesday. HIGHLIGHTS * Ametek AME.N : RBC raises target price to $257 from $229 *
02-04 14:59
美股大行评级 | 高露洁棕榄、再生元制药、伊士曼化工、威瑞森、Ameris、丘奇＆德怀特等获多家大行上调目标价
今日重点评级关注：Benchmark：维持Charter Communications"买入"评级，目标价从425美元升至455美元；BTIG：维持LifeStance Health Gr"买入"评级，目标价从10美元升至11美元
02-03 09:06
